Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
New And Existing Blockbusters Expected To Fill Future Revenue Gaps
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.
You may also be interested in...
Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.